HCW Biologics Inc.
HCWB
$6.02
$0.132.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.93% | -99.55% | -70.18% | -50.02% | -0.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.93% | -99.55% | -70.18% | -50.02% | -0.63% |
| Cost of Revenue | -98.81% | -99.20% | -70.52% | -49.71% | -12.74% |
| Gross Profit | -99.28% | -99.84% | -68.73% | -51.20% | 49.83% |
| SG&A Expenses | -81.14% | -58.15% | -60.53% | -27.52% | 295.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -75.99% | -53.94% | -59.85% | -30.59% | 181.59% |
| Operating Income | 74.96% | 47.08% | 58.58% | 27.33% | -206.75% |
| Income Before Tax | 87.38% | 70.58% | 68.42% | 20.98% | -254.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.38% | 70.58% | 68.42% | 20.98% | -254.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.38% | 70.58% | 68.42% | 20.98% | -254.99% |
| EBIT | 74.96% | 47.08% | 58.58% | 27.33% | -206.75% |
| EBITDA | 76.86% | 51.08% | 64.00% | 25.80% | -224.31% |
| EPS Basic | 58.00% | 75.49% | 73.12% | 24.94% | -237.04% |
| Normalized Basic EPS | 86.03% | 53.18% | 62.77% | 24.95% | -208.36% |
| EPS Diluted | 58.00% | 75.49% | 73.12% | 24.94% | -237.04% |
| Normalized Diluted EPS | 86.03% | 53.18% | 62.77% | 24.95% | -208.36% |
| Average Basic Shares Outstanding | 88.25% | 20.02% | 17.51% | 5.28% | 5.32% |
| Average Diluted Shares Outstanding | 88.25% | 20.02% | 17.51% | 5.28% | 5.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |